VLP Immunotherapy Combined with Ablation for HCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are limited by the immunosuppressive tumor microenvironment, with checkpoint inhibitors showing limited efficacy as single agents, and there is a need for a robust in situ vaccination approach that combines immunotherapy with liver-directed therapies to effectively treat HCC and related disorders.
Innovation Solution
A multi-modal in situ vaccination approach combining cryoablation with plant virus-based nanotechnology, specifically using VLP nanoparticles from the cowpea mosaic virus (CPMV) to activate innate immune cells and recruit immune cells to process tumor-associated antigens, along with the administration of immune checkpoint inhibitors to reprogram the tumor microenvironment and induce systemic antitumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used as single agents for HCC treatment, then immune response is activated, but survival improvement is limited due to immunosuppressive tumor microenvironment
Solution Approach 1:
The patent combines checkpoint inhibitors with in situ vaccination (ablation therapy) to create a synergistic effect. The ablation releases tumor antigens that serve as vaccines, while checkpoint inhibitors block immune suppression, together overcoming the immunosuppressive microenvironment more effectively than checkpoint inhibitors alone.
Solution Approach 2:
The patent introduces adjuvants as intermediaries that enhance the immune response to tumor antigens released during ablation. These adjuvants act as mediators between the ablation-induced antigen release and the checkpoint inhibitor-mediated immune activation, boosting the overall efficacy.
2Reliability
If combination CPI atezolizumab plus bevacizumab is used, then survival is improved versus sorafenib, but treatment complexity and cost increase
Solution Approach 1:
The patent merges ablation therapy with immunotherapy in a single integrated treatment approach. This combination delivers both local tumor control and systemic immune activation, achieving survival benefits comparable to or exceeding dual-agent immunotherapy while potentially simplifying the treatment paradigm.
3Adaptability or versatility
If in situ vaccination approach is implemented by combining ablation with immunotherapy, then systemic antitumor immunity is activated, but treatment protocol complexity increases
Solution Approach 1:
The patent segments the treatment into distinct phases: ablation phase for local tumor control and antigen release, followed by immunotherapy phase for systemic immune activation. This segmentation allows each component to be optimized independently while maintaining overall protocol manageability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to significant reduction in tumor growth, activation of immune cells, and durable antitumor immunity, providing protection against residual and metastatic cancer, as demonstrated by the synergistic effect of cryoablation and CPMV in preclinical models.
Implementation Method 1
combining ablation such as cryoablation to kill tumor cells and release tumor-associated antigens
Implementation Method 2
VLP nanoparticles, e.g., from the cowpea mosaic virus (CPMV) are delivered into the tumor at the time of cryoablation, as CPMV is a highly potent adjuvant; when administered intratumorally, CPMV-primed immunostimulation leads to recruitment and activation of innate immune cells to process tumor-associated antigens
Data Source
AI summary
Provided herein is a novel, multimodal in situ vaccination approach to treat cancer by combining ablation with administration of the naturally occurring plant virus or virus-like particle (VLP) nanoparticles such as cowpea mosaic virus (CPMV), a plant virus-based immunoadjuvant.